<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bdrx-20240606.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001643918</identifier>
        </entity>
        <period>
            <startDate>2025-05-02</startDate>
            <endDate>2025-05-02</endDate>
        </period>
    </context>
    <context id="From2025-05-022025-05-02_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001643918</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-02</startDate>
            <endDate>2025-05-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-02" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentCreationDate contextRef="AsOf2025-05-02" id="Fact000004">2025-05-02</dei:DocumentCreationDate>
    <dei:EntityFilerCategory contextRef="AsOf2025-05-02" id="Fact000005">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-02" id="Fact000006">0001643918</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-02" id="xdx2ixbrl0011">POS AM</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-02" id="Fact000012">Biodexa Pharmaceuticals PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-02" id="Fact000013">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-02" id="Fact000014">1 Caspian Point</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-02" id="Fact000015">Caspian Way</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-02" id="Fact000016">Cardiff</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-02" id="Fact000017">CF10 4DQ</dei:EntityAddressPostalZipCode>
    <dei:CountryRegion contextRef="AsOf2025-05-02" id="Fact000018">+44</dei:CountryRegion>
    <dei:CityAreaCode contextRef="AsOf2025-05-02" id="Fact000019">29</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-02" id="Fact000020">20480 180</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000021">Donald J. Puglisi</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000022">850 Library Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000023">Suite 204</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000024">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000025">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000026">19711</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000027">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-05-022025-05-02_dei_BusinessContactMember"
      id="Fact000028">738-6680</dei:LocalPhoneNumber>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-02" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="AsOf2025-05-02" id="Fact000030">This Post-Effective Amendment
No. 1 (this &#x201c;Post-Effective Amendment No. 1&#x201d;) to the Registration Statement on Form F-1 (File No. 333-279994) (the &#x201c;Registration
Statement&#x201d;) is being filed pursuant to our undertaking in the Registration Statement to update and supplement information contained
in the Registration Statement, as originally filed on June 6, 2024, and declared effective by the Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) on June 14, 2024, as to incorporate by reference the Company&#x2019;s Annual Report on Form 20-F for the year ended
December 31, 2024, as filed with the SEC on April 11, 2025. The Registration Statement originally covered a resale (the &#x201c;Offering&#x201d;)
by the selling shareholders identified in this prospectus, of up to an aggregate of 2,486,190,000 ordinary shares, nominal value &#xa3;0.0005
per share (the &#x201c;Ordinary Shares&#x201d;), of Biodexa Pharmaceuticals PLC, represented by 248,619 American Depositary Shares (the
&#x201c;Depositary Shares&#x201d;) consisting of (i) 2,421,630,000 Ordinary Shares represented by 242,163 Depositary Shares, issuable upon
the exercise of warrants issued in a May 2024 private placement, and (ii) 64,560,000 Ordinary Shares represented by 6,456 Depositary Shares,
issuable upon the exercise of Placement Agent warrants issued in such private placement.

&#160;

The information included in this filing updates
the Registration Statement and the prospectus contained therein.

&#160;

No additional securities are being registered
under this Post-Effective Amendment No. 1. Accordingly, this Post-Effective Amendment No. 1 concerns only the offer and sale of Ordinary
Shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised.

&#160;

All
applicable registration fees were paid at the time of the original filing of the Registration Statement.</dei:AmendmentDescription>
</xbrl>
